Compare JUBILANT LIFE SCIENCES with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GSK PHARMA JUBILANT LIFE SCIENCES/
GSK PHARMA
 
P/E (TTM) x 14.8 227.3 6.5% View Chart
P/BV x 2.8 11.7 23.6% View Chart
Dividend Yield % 0.5 1.4 39.9%  

Financials

 JUBILANT LIFE SCIENCES   GSK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
GSK PHARMA
Mar-19
JUBILANT LIFE SCIENCES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8983,595 25.0%   
Low Rs6181,253 49.3%   
Sales per share (Unadj.) Rs572.0184.7 309.8%  
Earnings per share (Unadj.) Rs36.226.3 137.8%  
Cash flow per share (Unadj.) Rs59.529.2 204.1%  
Dividends per share (Unadj.) Rs4.5020.00 22.5%  
Dividend yield (eoy) %0.60.8 72.0%  
Book value per share (Unadj.) Rs301.9126.3 239.0%  
Shares outstanding (eoy) m159.28169.40 94.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.313.1 10.1%   
Avg P/E ratio x20.992.2 22.7%  
P/CF ratio (eoy) x12.783.1 15.3%  
Price / Book Value ratio x2.519.2 13.1%  
Dividend payout %12.476.1 16.3%   
Avg Mkt Cap Rs m120,694410,626 29.4%   
No. of employees `0002.45.0 48.2%   
Total wages/salary Rs m19,2605,372 358.5%   
Avg. sales/employee Rs Th38,120.66,306.7 604.4%   
Avg. wages/employee Rs Th8,058.41,083.1 744.0%   
Avg. net profit/employee Rs Th2,414.3898.0 268.9%   
INCOME DATA
Net Sales Rs m91,10831,281 291.3%  
Other income Rs m3571,023 34.9%   
Total revenues Rs m91,46632,304 283.1%   
Gross profit Rs m17,3906,009 289.4%  
Depreciation Rs m3,709486 763.2%   
Interest Rs m2,1986 36,635.0%   
Profit before tax Rs m11,8406,540 181.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,802287 -976.4%   
Tax Rs m3,2682,373 137.7%   
Profit after tax Rs m5,7704,454 129.5%  
Gross profit margin %19.119.2 99.4%  
Effective tax rate %27.636.3 76.1%   
Net profit margin %6.314.2 44.5%  
BALANCE SHEET DATA
Current assets Rs m45,84820,061 228.5%   
Current liabilities Rs m20,89714,543 143.7%   
Net working cap to sales %27.417.6 155.2%  
Current ratio x2.21.4 159.0%  
Inventory Days Days5757 100.0%  
Debtors Days Days5114 362.3%  
Net fixed assets Rs m65,49814,343 456.7%   
Share capital Rs m1591,694 9.4%   
"Free" reserves Rs m47,93019,704 243.2%   
Net worth Rs m48,08921,398 224.7%   
Long term debt Rs m42,4292 2,121,445.0%   
Total assets Rs m114,68539,113 293.2%  
Interest coverage x6.41,091.0 0.6%   
Debt to equity ratio x0.90 943,981.1%  
Sales to assets ratio x0.80.8 99.3%   
Return on assets %6.911.4 60.9%  
Return on equity %12.020.8 57.6%  
Return on capital %12.431.9 38.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,422534 2,326.2%   
Fx outflow Rs m17,2277,091 242.9%   
Net fx Rs m-4,805-6,557 73.3%   
CASH FLOW
From Operations Rs m11,2153,994 280.8%  
From Investments Rs m-10,118-1,433 705.9%  
From Financial Activity Rs m6,574-3,584 -183.5%  
Net Cashflow Rs m7,612-1,023 -744.0%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 50.7 6.9%  
Indian inst/Mut Fund % 8.7 10.2 85.3%  
FIIs % 21.2 23.8 89.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 15.4 137.0%  
Shareholders   23,815 102,036 23.3%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   NOVARTIS  ASTRAZENECA PHARMA  BIOCON   STERLING BIOTECH  NATCO PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets continued to trade on a volatile note and ended on a flat note today. At the closing bell, the BSE Sensex stood lower by 24 points (down 0.1%).

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

My Best Trading Ideas When Interest Rates Are So Low(Fast Profits Daily)

Jul 23, 2020

India's interest rates are lower than the inflation rate. Here are the best trades for this situation.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Gold or Silver: Which One Should You Buy Now?(Fast Profits Daily)

Jul 24, 2020

Silver and gold are both vying for your attention. Which is the better trade today?

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 5, 2020 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - CIPLA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS